Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2018 共识文件：改善亚洲高血压患者的管理

2018-01-08 亚洲心血管专家小组（统称） Hypertension. 2018 Jan 8

高血压

高血压是世界范围内导致死亡和心血管疾病的主要原因，在亚洲国家，卒中尤其是出血性卒中，非缺血型心衰更加常见。本文主要针对优化亚洲高血压患者的管理提出共识声明，涉及亚洲人群高血压和心血管疾病的特点，血压监测，血管年龄，老年患者，糖尿病，慢性肾病，房颤，卒中二级预防，抗高血压治疗等。

中文标题：

2018 共识文件：改善亚洲高血压患者的管理

英文标题：

Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics

发布机构：

亚洲心血管专家小组（统称）

发布日期：

2018-01-08

简要介绍：

高血压是世界范围内导致死亡和心血管疾病的主要原因，在亚洲国家，卒中尤其是出血性卒中，非缺血型心衰更加常见。本文主要针对优化亚洲高血压患者的管理提出共识声明，涉及亚洲人群高血压和心血管疾病的特点，血压监测，血管年龄，老年患者，糖尿病，慢性肾病，房颤，卒中二级预防，抗高血压治疗等。

拓展指南：与高血压相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 共识文件：改善亚洲高血压患者的管理)] GetToolGuiderByIdResponse(projectId=1, id=3a5701c0015a34c7, title=2018 共识文件：改善亚洲高血压患者的管理, enTitle=Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics, guiderFrom=Hypertension. 2018 Jan 8, authorId=null, author=, summary=高血压是世界范围内导致死亡和心血管疾病的主要原因，在亚洲国家，卒中尤其是出血性卒中，非缺血型心衰更加常见。本文主要针对优化亚洲高血压患者的管理提出共识声明，涉及亚洲人群高血压和心血管疾病的特点，血压监测，血管年龄，老年患者，糖尿病，慢性肾病，房颤，卒中二级预防，抗高血压治疗等。 , cover=, journalId=null, articlesId=null, associationId=1580, associationName=亚洲心血管专家小组（统称）, associationIntro= , copyright=0, guiderPublishedTime=Mon Jan 08 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>高血压是世界范围内导致死亡和心血管疾病的主要原因，在亚洲国家，卒中尤其是出血性卒中，非缺血型心衰更加常见。本文主要针对优化亚洲高血压患者的管理提出共识声明，涉及亚洲人群高血压和心血管疾病的特点，血压监测，血管年龄，老年患者，糖尿病，慢性肾病，房颤，卒中二级预防，抗高血压治疗等。 </P>拓展指南：<STRONG>与<FONT color=red>高血压</FONT>相关指南：</STRONG><BR> <UL> <LI><A title="2017 ACR适宜性标准：肾血管性高血压" target=_blank href="//www.sandwebs.com/guideline/show_article.do?id=465911c001526564">2017 ACR适宜性标准：肾血管性高血压</A> <LI><A title=老年高血压的诊断与治疗中国专家共识（2017版） target=_blank href="//www.sandwebs.com/guideline/show_article.do?id=439a01c0015199c6">老年高血压的诊断与治疗中国专家共识（2017版）</A> <LI><A title="2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH / ASPC / NMA / PCNA成人高血压预防，检测，评估和管理指南" target=_blank href="//www.sandwebs.com/guideline/show_article.do?id=38cdd1c0015192a7">2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH / ASPC / NMA / PCNA成人高血压预防，检测，评估和管理指南</A> <LI><A title="ADA 关于糖尿病合并高血压的最新立场声明的解读" target=_blank href="//www.sandwebs.com/guideline/show_article.do?id=3aad31c00151809e">ADA 关于糖尿病合并高血压的最新立场声明的解读</A> <LI><A title=高血压患者心率管理中国专家共识 target=_blank href="//www.sandwebs.com/guideline/show_article.do?id=b519c1c0015091a8">高血压患者心率管理中国专家共识</A> 更多信息请点击：<A target=_blank href="//www.sandwebs.com/guideline/list.do?q=%E9%AB%98%E8%A1%80%E5%8E%8B">有关高血压更多指南</A></LI></UL>, tagList=[TagDto(tagId=274, tagName=高血压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8424, appHits=650, showAppHits=0, pcHits=6168, showPcHits=2323, likes=200, shares=17, comments=20, approvalStatus=1, publishedTime=Sat Jan 13 23:50:02 CST 2018, publishedTimeString=2018-01-08, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Jan 13 23:50:02 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 19:36:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 共识文件：改善亚洲高血压患者的管理)])
2018 共识文件：改善亚洲高血压患者的管理
下载请点击：
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=282371, encodeId=dc612823e1c3, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 27 00:13:19 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280210, encodeId=12b228021087, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 20 03:33:19 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279087, encodeId=bd6a2e9087b2, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jan 16 13:52:39 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278771, encodeId=f7162e8771ea, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jan 15 17:55:19 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278750, encodeId=94612e8750a0, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Jan 15 14:51:07 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-27 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=282371, encodeId=dc612823e1c3, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 27 00:13:19 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280210, encodeId=12b228021087, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 20 03:33:19 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279087, encodeId=bd6a2e9087b2, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jan 16 13:52:39 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278771, encodeId=f7162e8771ea, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jan 15 17:55:19 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278750, encodeId=94612e8750a0, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Jan 15 14:51:07 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-20 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=282371, encodeId=dc612823e1c3, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 27 00:13:19 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280210, encodeId=12b228021087, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 20 03:33:19 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279087, encodeId=bd6a2e9087b2, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jan 16 13:52:39 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278771, encodeId=f7162e8771ea, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jan 15 17:55:19 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278750, encodeId=94612e8750a0, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Jan 15 14:51:07 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-16 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=282371, encodeId=dc612823e1c3, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 27 00:13:19 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280210, encodeId=12b228021087, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 20 03:33:19 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279087, encodeId=bd6a2e9087b2, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jan 16 13:52:39 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278771, encodeId=f7162e8771ea, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jan 15 17:55:19 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278750, encodeId=94612e8750a0, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Jan 15 14:51:07 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 137****9095

    henhao

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=282371, encodeId=dc612823e1c3, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 27 00:13:19 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280210, encodeId=12b228021087, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 20 03:33:19 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279087, encodeId=bd6a2e9087b2, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jan 16 13:52:39 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278771, encodeId=f7162e8771ea, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jan 15 17:55:19 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278750, encodeId=94612e8750a0, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Jan 15 14:51:07 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 xiaotao112411

    学习学习学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

ADA 关于糖尿病合并高血压的最新立场声明的解读

暂未更新 · 2017-10-30

高血压患者心率管理中国专家共识

中国医师协会高血压专业委员会 · 2017-08-30

高血压合理用药指南（第2版）

国家卫生计生委合理用药专家委员会 · 2017-07-20

≥60岁高血压病人控制血压在较高或较低水平的药物治疗——美国医师协会和美国家庭医师学会临床实践指南

暂未更新 · 2017-08-30

高血压中医诊疗指南

中华中医药学会(CACM,China Association of Chinese Medcine) · 2011-12-10

2017 TES科学声明：内分泌性高血压的筛查

美国内分泌学会(TES,The Endocrine Society) · 2017-03-22

Baidu
map
Baidu
map
Baidu
map